Methods of manufacturing stable aqueous formulations of adalimumab
First Claim
Patent Images
1. A method of manufacturing an aqueous adalimumab formulation, wherein:
- the aqueous adalimumab formulation comprises;
(i) adalimumab;
(ii) buffer; and
(iii) stabilizer; and
wherein the formulation is free of polyol, has a pH of about 5 to about 6, and is stable for one week at 40°
C. or two weeks at 25°
C., andthe method comprises (a) creating a formulation buffer comprising the buffer of the aqueous adalimumab formulation; and
(b) contacting a solution comprising adalimumab with the formulation buffer.
6 Assignments
0 Petitions
Accused Products
Abstract
The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.
-
Citations
20 Claims
-
1. A method of manufacturing an aqueous adalimumab formulation, wherein:
-
the aqueous adalimumab formulation comprises;
(i) adalimumab;
(ii) buffer; and
(iii) stabilizer; and
wherein the formulation is free of polyol, has a pH of about 5 to about 6, and is stable for one week at 40°
C. or two weeks at 25°
C., andthe method comprises (a) creating a formulation buffer comprising the buffer of the aqueous adalimumab formulation; and
(b) contacting a solution comprising adalimumab with the formulation buffer. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8)
-
-
9. A method of manufacturing an aqueous adalimumab formulation, wherein:
-
the aqueous adalimumab formulation has a pH of about 5 to about 6 and comprises; (i) adalimumab; (ii) buffer, free of citrate, and consisting essentially of histidine, succinate, or both; and (iii) stabilizer consisting essentially of; (a) glycine, arginine, or both;
or(a) and (b);
where (b) is sodium chloride, sodium sulfate, or both,wherein the composition is free of polyol, and is stable for one week at 40°
C. or two weeks at 25°
C., andthe method comprises (a) creating a formulation buffer comprising the buffer of the aqueous adalimumab formulation; and
(b) contacting a solution comprising adalimumab with the formulation buffer. - View Dependent Claims (10, 11, 12, 13, 14, 15)
-
-
16. A method of manufacturing an aqueous adalimumab formulation, wherein:
-
the aqueous adalimumab composition comprises adalimumab and a citrate-free buffer, is free of a polyol, has a pH of about 5 to about 6, and is stable for one week at 40°
C. or two weeks at 25°
C., andthe method comprises (a) creating a formulation buffer comprising the buffer of the aqueous adalimumab formulation; and
(b) contacting a solution comprising adalimumab with the formulation buffer. - View Dependent Claims (17, 18, 19, 20)
-
Specification